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Background: The peripheral immune-derived opioid analgesic pathway has been well established 
as a novel target in the clinical pain management of a number of painful pathologies, including acute 
inflammatory pain, neuropathic pain, and rheumatoid arthritis.
Objective: Our objective was to engineer targeted nanoparticles that mimic immune cells in peripheral 
pain control to deliver opioids, in particular loperamide HCl, specifically to peripheral opioid receptors 
to induce analgesic and anti-inflammatory actions for use in painful inflammatory conditions. This 
peripheral analgesic system is devoid of central opioid mediated side effects (e.g., respiratory depression, 
sedation, dependence, tolerance).
Study Design: A randomized, double blind, controlled animal trial.
Methods: Thirty-six adult male Wistar rats (200 - 250 g) were randomly divided into 6 groups: loperamide 
HCl-encapsulated anti-ICAM-1 immunoliposomes, naloxone methiodide + loperamide HCl-encapsulated anti-
ICAM-1 immunoliposomes, loperamide HCl-encapsulated liposomes, empty anti-ICAM-1 immunoliposomes, 
empty liposomes, and loperamide solution. Animals received an intraplantar injection of 150 µL Complete 
Freund’s Adjuvant (CFA) into the right hindpaw and experiments were performed 5 days post-CFA injection, 
which corresponded to the peak inflammatory response. All formulations were administered intravenously 
via tail vein injection. The dose administered was 200 µL, which equated to 0.8 mg of loperamide HCl for the 
loperamide HCl treatment groups (sub-therapeutic dose). Naloxone methiodide (1 mg/kg) was administered 
via intraplantar injection, 15 minutes prior to loperamide-encapsulated anti-ICAM-1 immunoliposomes. An 
investigator blinded to the treatment administered assessed the time course of the antinociceptive and anti-
inflammatory effects using a paw pressure analgesiometer and plethysmometer, respectively. Biodistribution 
studies were performed 5 days post-CFA injection with anti-ICAM-1 immunoliposomes and control liposomes 
via tail vein injection using liquid scintillation counting (LSC).
Results: Administration of liposomes loaded with loperamide HCl, and conjugated with antibody to 
intercellular adhesion molecule-1 (anti-ICAM-1), exerted analgesic and anti-inflammatory effects exclusively 
in peripheral painful inflamed tissue. These targeted nanoparticles produced highly significant analgesic 
and anti-inflammatory effects over the 48 hour time course studied following intravenous administration 
in rats with Complete Freund’s Adjuvant-induced inflammation of the paw. All control groups showed no 
significant antinociceptive or anti-inflammatory effects. Our biodistribution study demonstrated specific 
localization of the targeted nanoparticles to peripheral inflammatory tissue and no significant uptake into 
the brain.
Limitations: In vivo studies were performed in the well-established rodent model of acute 
inflammatory pain. We are currently studying this approach in chronic pain models known to have 
clinical activation of the peripheral immune-derived opioid response.
Conclusions: The study presents a novel approach of opioid delivery specifically to injured tissues for 
pain control. The study also highlights a novel anti-inflammatory role for peripheral opioid targeting, 
which is of clinical relevance. The potential also exists for the modification of these targeted nanoparticles 
with other therapeutic compounds for use in other painful conditions.
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endogenous analgesia is elicited by immune cells 
entering inflamed tissue and releasing opioid peptides 
that activate up-regulated opioid receptors on sensory 
nerve terminals (1) (Fig. 1). Inflammation has been 
shown to increase the expression of opioid peptides 
within these immune cells (4). All opioid peptides as 
well as their mRNA transcripts encoding their precursor 
proteins have been identified within immune cells, with 
β-endorphin being the most prominent (4,5).
We have previously identified a physical outcome 
associated with a direct interaction between the im-
mune system and the peripheral nervous system in pe-
ripheral analgesia (6). Adhesion molecules, in particular 
intercellular adhesion molecule-1 (ICAM-1), have been 
shown to play an important role in the transmigration 
of opioid-containing immune cells to injured tissue, 
as well as the direct binding of these immune cells to 
sensory neurons to produce adequate analgesia (Fig. 
1). Immunohistochemical studies have revealed ICAM-
1 expression on both nonhaematopoietic cells (e.g., 
Pain is a major health problem having a significant impact not just on sufferers, but also on the broader community and economy. Painful 
pathologies such as neuropathic pain and arthritis and 
musculoskeletal conditions are highly prevalent and 
large contributors to illness, pain, and disability. Despite 
the wide-ranging conditions and symptoms, the main 
subgroups share a significant underlying inflammatory 
component, and are limited by effective and safe 
clinical management options (1,2). The peripheral 
immune-derived opioid analgesic pathway has been 
well established as a novel target in the clinical pain 
management of these conditions (1). In particular at 
early stages of inflammation, both peripheral and 
central opioid receptors are involved in antinociceptive 
effects, whereas at later stages endogenous analgesia 
is mediated exclusively by peripheral opioid receptors 
(3). Therefore, peripheral opioid mechanisms of pain 
control become more prevalent with the duration 
and severity of inflammation (3). In the periphery, 
Fig. 1. Mimicking the migration of  opioid-containing immune cells and opioid secretion within inflamed tissue using targeted 
nanoparticles. Adhesion molecules interact with their respective ligands to facilitate endothelial transmigration of  immune cells. In 
response to stress or releasing agents (e.g., corticotropin-releasing hormone or interleukin-1), the immune cells secrete opioid peptides. 
Opioid peptides or exogenous opioids bind to opioid receptors on primary afferent neurons, leading to analgesia. Direct adhesion 
between opioid-containing immune cells and peripheral sensory neurons may be necessary to release opioid peptides within the effective 
range of  peripheral opioid receptors. The immune cells, depleted of  opioids, then migrate to regional lymph nodes.
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vascular endothelium) as well as haematopoietic cells 
(e.g., leukocytes and macrophages). Although ICAM-1 
expression is low in both nonhaematopoietic cells and 
resting peripheral blood leukocytes, it is upregulated 
by cytokines [e.g., tumor necrosis factor-alpha (TNF-α), 
interleukin-1 (IL-1)] and in activated T- and B- lympho-
cytes, respectively (7).
To mimic the endogenous peripheral opioid analge-
sic response in injured tissue, we used opioid-containing 
immune cells as a structural platform in the design of 
synthetic targeted nanoparticles that have the ability 
to release encapsulated opioids directly at the site of 
inflammation. In this study the highly potent peripheral 
mu-opioid receptor (MOR) agonist, loperamide HCl, was 
incorporated in liposomes directed towards ICAM-1, to 
create a delivery system with the unique properties of 
binding to adhesion molecules that are significantly 
increased at the site of tissue injury. Loperamide HCl is 
a piperidine derivative (8) that was developed to mimic 
the effect of morphine on the intestinal tract as an 
antidiarrhoeal agent, without any central morphinomi-
metic effects (9). It exhibits high affinity and selectivity 
for peripheral mu-opioid receptors, but does not have 
analgesic effects when administered orally or intrave-
nously due to its physicochemical properties (1,10-14).
The design of peripherally acting analgesics may 
have widespread potential for clinical use by optimiz-
ing drug concentrations at the site of injury thereby 
avoiding systemically active drug levels, adverse sys-
temic effects, or drug interactions, whilst maintaining 
effective analgesia. The immune-cell derived opioid 
pathway is devoid of typical opioid mediated side 
effects (e.g., respiratory depression, sedation, depen-
dence, tolerance, constipation) (15), which will have 
important implications for the management of chronic 
pain. A major advantage of targeting peripheral opi-
oid receptors is their mechanism of action of inhibiting 
calcium (and possibly sodium) channels, which simply 
renders the nociceptor less excitable to the plethora 
of stimulating molecules expressed in damaged tissue. 
Therefore, peripherally acting opioids can prevent and 
reverse the action of multiple excitatory agents simul-
taneously (16). Therefore it may be used to produce 
clinically significant and effective analgesia in a range 
of inflammatory pain conditions. This study is the first 
to apply the concept of disease-site targeting to mimic 
the inherent opioid containing immune cell response, 
shown to produce both site-directed analgesic and 
anti-inflammatory actions.
Methods 
Liposome-related Materials
1,2-distearoyl-sn-glycero-2-phosphocholine (DSPC) 
and 1-{8-[4(p-maleimidophenyl)butaroylamino]-3,6-
dioxaloctyl}-2,3-distearyl glyceryl-dl-ether (MPB- 
TRIG-DSGE) were purchased from Northern Lipid 
(Vancouver, Canada). The CBQCA protein assay kit 
was from Invitrogen (Melbourne, Australia). Choles-
terol, N-succinimidyl-3- (2-pyridyldithio) propionate 
(SPDP), and Sepharose CL-4B were from Sigma-Aldrich 
(Sydney, Australia). Tris(2-Carboxyethyl) phosphine 
Hydrochloride (TCEP) was purchased from Quantum 
Scientific (Queensland, Australia). Rabbit IgG antibody 
and anti-ICAM monoclonal antibody were obtained 
from Chemicon International Inc. (Melbourne, Austra-
lia). PD-10 column was from GE Healthcare Bio-Sciences 
Pty. Ltd. (Sydney, Australia). All other chemicals and 
solvents were of at least analytical grade.
Cell-related Materials
Reagents were obtained from the following 
sources: penicillin, streptomycin, Dulbecco’s Phosphate 
Buffered Saline, and RPMI 1640 media were obtained 
from GIBCO/Life Technologies (Melbourne, Australia); 
fetal calf serum, collagenase (Type II), dimethylsulfox-
ide (DMSO), trypan blue solution 0.4%, tumor necrosis 
factor-alpha (TNF- α) and all buffer reagents were from 
Sigma-Aldrich, (Sydney, NSW, Australia); trypsin- EDTA 
(1:250) was from Australian Biosearch (Trace Plastics) 
(Perth, Australia). FITC-conjugated mouse anti-rat 
OX-43 monoclonal antibody was from Invitrogen (Mel-
bourne, Australia). All other reagents were of analyti-
cal grade. The hemacytometer used for cell counts was 
purchased from Hausser Scientific (Horsham, PA). The 
fluorescent plate reader Novostar and its correspond-
ing software (Novostar) were obtained from BMG 
Labtechnologies (Mt Eliza, Victoria, Australia).
Preparation of Conventional Liposomes
Conventional liposomes were prepared according 
to the method of dried lipid film hydration. Briefly, 
16 mg DSPC and 4 mg cholesterol (molar ratio of 2:1) 
(and 4 mg loperamide HCl) were solubilized in 6 mL 
chloroform:methanol (2:1, v/v) in a 50 mL round bot-
tomed flask and dried by rotary evaporation under re-
duced pressure (200 mbar; 15 min; 60oC). The resultant 
thin lipid film was hydrated with the addition of 1 mL 
of PBS (pH 7.4) and resuspended in a 65oC water bath. 
The resultant multilamellar dispersions were reduced 
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in size and lamellarity by probe sonication (60 amps; 5 
min) at 65oC. Liposomes were stored at 4oC, under nitro-
gen gas and in the dark, and were used within 7 days.
Preparation of Immunoliposomes
Immunoliposomes were prepared according to the 
method of dried lipid film hydration using our novel 
method as previously described (17). Liposomes com-
posed of DSPC and cholesterol (molar ratio 2:1) con-
taining MPB-TRIG-DSGE at 1.5 mol percent of DSPC as a 
coupling lipid were prepared according to the method 
of dried lipid film hydration in PBS buffer (pH 7.4). 
The resulting multilamellar dispersions were reduced 
in size and lamellarity by ultrasonication at 60 amp 
for 5 minutes. The activated liposome suspension was 
immediately mixed with thiolated antibody at room 
temperature. Thiolated antibodies were prepared by 
conjugating anti-ICAM-1 monoclonal antibodies (25 
µg) or non-specific rabbit IgG (25 µg) with a heterobi-
functional reagent N-succinimidyl-3-(2-pyridyldithio) 
propionate (SPDP) (6.25 mg/mL; SPDP/mAb molar ratio 
= 10:1). Excess SPDP was removed through a PD-10 
column equilibrated with distilled water. Fractions 
containing pyridyldithiopropionated-Ab (PDP-Ab) 
conjugates (assessed by absorbance in 280 nm) were 
pooled and lyophilized to form a solid product, which 
was then stored at 4oC under nitrogen gas. To produce 
thiolated- Ab (Ab-SH), PDP-Ab was reduced with 5 mM 
TCEP for 5 minutes. Absorbance was checked at 280 nm 
(protein concentration) and 343 nm (SPDP modifica-
tion), in order to ensure stability of the compound as 
described above. The Ab-SH was mixed immediately 
with liposomes and incubated for one hour at room 
temperature with stirring in the dark. Unconjugated Ab 
was removed by size exclusion chromatography using a 
Sepharose CL-4B column (1cm x 16cm), which excluded 
liposomes in the void volume, or by TLX ultracentrifu-
gation (Optima) (100 000 g; 45 minutes). Immunolipo-
somes were stored at 4oC, under nitrogen gas and in 
the dark, and were used within 7 days. The size distri-
bution of the liposomal dispersion was determined by 
dynamic laser light scattering (Zetasizer 3000, Malvern, 
Worcestershire, United Kingdom). Loperamide-HCl en-
capsulated anti-ICAM-1 immunoliposomes had a mean 
particle size of 286 nm and a polydispersity index of 
0.307. The size and polydispersity of the control lipo-
some formulations were similar. Quantification of the 
amount of antibody associated with liposomes was 
determined using the CBQCA protein assay (Invitrogen) 
using bovine serum albumin for the preparation of the 
standard curve. The conjugation efficiency equated to 
96% and 99% for anti-ICAM-1 immunoliposomes and 
rabbit IgG immunoliposomes, respectively. This proce-
dure resulted in high loperamide HCl encapsulation 
efficiency of > 99%, which equated to 3.981 ± 0.078 
mg/mL of loperamide HCl encapsulated in the liposome 
suspension. Loperamide HCl solution was prepared by 
dissolving 4 mg loperamide HCl in 50% DMSO/50% PBS 
pH 7.4.
Liposome Stability Assay
The dialysis technique was used to evaluate the in 
vitro stability of liposomes encapsulating loperamide HCl 
by separating the encapsulated from the non-encapsu-
lated drug. Release properties of loperamide HCl were 
measured as the accumulative release percentages in an 
outer medium during 48 hours to compare the stability 
of the liposome formulations in phosphate buffered sa-
line pH 7.4 (PBS) and 50% fetal calf serum (FCS) at 37oC. 
The degree of stability of the nanoparticles influences 
their circulation time and controlled release capabil-
ity when administered intravenously. To circumvent 
potential solubility issues of loperamide HCl across the 
dialysis membrane, a modified assay was developed to 
assess true release of loperamide HCl from the liposomes 
without surpassing saturation point. In brief, 50 µl of 4 
mg/mL loperamide HCl-encapsulated liposome suspen-
sion (equivalent to 200 µg loperamide HCl) was added 
in a dialysis bag with either PBS pH 7.4 or 50% FCS to 
a volume of 10 mL. The dialysis system was suspended 
in a release volume of 40 mL PBS at 37oC and rotated 
at 200 rpm. For control groups, 4 mg of loperamide 
HCl was dissolved in 200 mL PBS pH 7.4, and 10 mL of 
this solution (equivalent to 200 µg loperamide HCl) was 
placed in a dialysis bag and stability was assessed using 
the above dialysis method. At scheduled intervals, 200 
µl of the release medium was collected for HPLC assay. 
The same volume of fresh PBS buffer at the same tem-
perature was added immediately to maintain constant 
release volume. Calibration curves were established by 
plotting the standard concentrations of loperamide HCl 
dissolved in PBS pH 7.4 versus the peak height. The lop-
eramide HCl release percentage was obtained according 
to: Drug release (%) = (Dt/D0) x 100%, where Dt and D0 
indicate the amount of drug released from the liposome 
suspension at certain intervals and the total amount of 
drug in the liposome suspension, respectively. At the end 
of the study, the liposome samples were recovered from 
the dialysis system, and lysed with ethanol for analysis 
for loperamide HCl content by HPLC.
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Cell Culture
Primary high endothelial venule cells (HEV) were 
isolated and cultured from rat lymph nodes as previ-
ously described (18). In brief, male Wistar rats were se-
dated by inhalation of 50% O2/50% CO2 and sacrificed 
by asphyxiation with 100% CO2. Popliteal lymph nodes 
were surgically collected under sterile conditions. The 
tissue was washed twice with Dulbecco’s Phosphate 
Buffered Saline (D-PBS with calcium chloride and mag-
nesium chloride) plus antibiotics (50 units/mL penicillin 
+ 50 µg/mL streptomycin) (DAB), and then incubated 
in 10% betadine in DAB for 10 minutes, before being 
washed 3 times with DAB. The tissue was minced finely 
with sharp-bladed scissors to dissociate the cells and al-
lowed to settle out of 20 mL DAB for 1 – 2 minutes. The 
cell-rich supernatant was discarded, and the tissue was 
washed 3 times with DAB, before being resuspended 
at 50 mg/mL in RPMI 1640 containing 10mM-NaHCO3, 
20mM-HEPES, 2mM-glutamine, antibiotics (RPMIInc) and 
0.5% type II collagenase. After shaking for 60 minutes 
at 37°C, the tissue was dispersed with a Pasteur pipette, 
resuspended in 10mL RPMIInc and the cells were disso-
ciated through a 100 µm nylon mesh supported in 23 
mm Millipore Swinnex filter holder. Isolated cells were 
collected by centrifugation at 250 g for 5 minutes and 
then plated in a tissue culture flask containing com-
plete medium (RPMI 1640 containing 20mM-NaHCO3 
and 2 mM-glutamine, 20% heat-inactivated (56°C; 
30 min) fetal calf serum, 100 IU/mL penicillin and 100 
µg/mL streptomycin). Cell were cultured in incubators 
maintained at 37°C in a humidified atmosphere of 5% 
CO2 in air. Feeding media was routinely replaced every 
48 – 72 hours. HEV cells were identified by FITC-con-
jugated OX-43 labeling under fluorescence microscopy, 
and further supported by ICAM-1 labeling. Viability 
and morphology of the cells were monitored by phase 
contrast microscopy and consistently found to be un-
changed throughout the experiments. Viable cells were 
counted using the Trypan Blue Exclusion method and a 
haemocytometer.
Specificity of Binding to ICAM-1 on HEV Cells
HEV cells were seeded in 96-well tissue culture 
plates at 4x104 cells per well in complete medium (RPMI 
1640 containing 20mM-NaHCO3 and 2mM-glutamine, 
20% heat-inactivated (56°C; 30 minutes) fetal calf se-
rum, 100 IU/mL penicillin and 100 µg/mL streptomycin) 
and activated with TNF-α (1 ng/mL) for 24 hours at 37oC 
in 5% CO2. The fluorescent dye DiI was incorporated 
into the phospholipid bilayer as a marker for the lipo-
somes. Following activation, liposomes were added to 
the wells and the cultures incubated for 2 hours at 4oC 
or 5 hours at 37oC. Binding was assessed in vitro after 
2 h of incubation at 4oC to determine exclusively cell 
binding, or after 5 hours of incubation at 37oC to de-
termine cell association. After washing cells to remove 
unbound liposomes, binding was then assessed via 
fluorimetric detection to assess exclusively cell bind-
ing at excitation/emission wavelengths corresponding 
to DiI (549nm/565nm) (POLARstar OPTIMA fluorescent 
microplate reader; BMG LABTECH Pty. Ltd.,Victoria, 
Australia). Background reading was assessed with cells 
incubated in medium alone.
Cellular Uptake of Liposomes
To evaluate cell association of ICAM-1 targeted 
immunoliposomes, HEV cells were plated in 96-well tis-
sue culture plates at an initial density of 4x104 cells per 
well and grown until confluent under the conditions 
described above. Before experiments, cell monolayers 
were activated with TNF-α (1 ng/mL) for 24 hours at 
37oC. After an exchange of the medium, cells were then 
incubated in serum-free medium containing fluores-
cent labeled liposomes for 2 hours at 4oC or 5 hours at 
37oC. Two temperatures were used in order to differ-
entiate receptor binding and internalization. At 4oC, it 
was expected that no receptor internalization occurred, 
whereas both receptor binding and internalization 
took place at 37oC (19,20). At the end of incubation, 
the cells were washed 3 times with ice-cold PBS before 
fluorimetric detection to assess extracellularly bound li-
posomes (Polarstar, BMG). Surface-bound fluorescence 
was released by acid wash (10 minutes 0.1M HCl) (21) 
before lysis of the cells with addition of 1% Triton-X100 
in PBS for 10 minutes at 37oC. Results retrieved by acid 
wash were expressed as extracellularly bound fluores-
cence, whereas fluorescence in the lysis fractions was 
expressed as internalized fluorescence. Background 
reading was assessed with solubilized cells without 
prior incubation with liposomes.
Animals and Induction of Inflammation
Male Wistar rats (200 - 250 g) (ARC, Australia) were 
anaesthetised by a brief exposure to 2% isoflurane (Ab-
bot, Cronulla, Australia) and received an intraplantar 
injection of 150 µl Complete Freund’s Adjuvant (CFA) 
(Sigma–Aldrich, Sydney, Australia) into the right hind-
paw. Animals were housed in groups of 2 or 3 per cage, 
under 12 h light-dark cycles in a room with controlled 
temperature (22°C) and humidity (60%). Rats had free 
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access to standard rodent chow and water, and were 
used after a minimum of 5 days acclimatization to 
the housing conditions. All animal experiments were 
performed with permission from the Animal Experi-
mentation and Ethics Committee at The University of 
Queensland and The University of Newcastle.
Assessment of Antinociception and 
Inflammation
Baseline measurements of paw pressure threshold 
(PPT) and paw volume were obtained prior to CFA in-
jection. On the basis of previous studies, experiments 
were performed 5 days post-CFA injection, which cor-
responded to the peak inflammatory response. Baseline 
measurements were again assessed 5 days following CFA 
injection before intravenous administration of loper-
amide HCl-encapsulated anti-ICAM-1 immunoliposomes 
or control liposome formulations via tail vein injection. 
The dose administered was 200 µl, which equated to 0.8 
mg of loperamide HCl for the loperamide HCl treatment 
groups. Naloxone methiodide (1mg/kg) was adminis-
tered via intraplantar injection, 15 minutes prior to lop-
eramide-encapsulated anti-ICAM-1 immunoliposomes. 
An investigator blinded to the treatment administered 
assessed the time course of the antinociceptive and anti-
inflammatory effects. Inflammation was assessed with a 
rat plethysmometer (Ugo Basile, Comerio, Italy). This in-
volves the placement of each paw into the displacement 
cell and the instrument measures displacement and 
interprets this as volume. Nociceptive thresholds were 
assessed using the paw pressure analgesiometer (Ugo 
Basile, Comerio, Italy), which involves a sliding weight 
scale and a blunt probe that places pressure on the paw 
against a plate surface. Animals respond by flinching or 
moving the paw. Cut-offs were set at 250 g for pressure 
threshold, which correspond to the maximum ethical 
load. PPTs were assessed at baseline, 15 minutes, 1 hour, 2 
hours, 4 hours, 7 hours, 10 hours, 24 hours, and 48 hours. 
Paw volumes were evaluated at baseline, 24 hours, and 
48 hours. During the experiments, the sequence of in-
flamed and non-inflamed paw testing was alternated to 
preclude order effects for PPT, and triplicate values were 
averaged.
Biodistribution Study
Biodistribution studies were performed 5 days 
post-CFA injection with anti-ICAM-1 immunoliposomes 
and control liposomes via tail vein injection using liquid 
scintillation counting (LSC). Liposomes were radiola-
belled with [3H]-CHE (PerkinElmer) with loperamide HCl 
loading at a specific ratio of 0.5 µci/µmol phospholipid. 
The use of [3H]-CHE is convenient for these studies be-
cause it is a stable, nonexchangeable, and nondegrad-
able marker of liposomes, thus providing an estimate 
of the cumulative liposome dose in tissue. The dose 
administered was 200 µl, which equated to 0.8 mg of 
loperamide HCl and 7.41 x 104 Bq. Biodistribution was 
assessed 7 hours after liposome injection, which corre-
sponded to peak antinociceptive effect of loperamide 
HCl-encapsulated anti-ICAM-1 immunoliposomes. At 
the scheduled time point, rats were sacrificed by as-
phyxiation with 100% CO2 and cervical dislocation. Paw 
tissues, brain, liver, and kidneys were removed, rinsed 
in physiological saline, and frozen at –20°C until further 
processing. Tissue samples were weighed into scintilla-
tion vials and prepared as per protocol described by 
PerkinElmer (22). Radioactivity was measured in terms 
of number of disintegrations per minute (DPM) of [3H]-
CHE of each tissue sample. The amount of radioactivity 
was then expressed as the number of Bq per gram of 
tissue using the following conversion: 1 Bq = 60 DPM.
Statistical Analyses
All data are expressed as means ± standard error 
of the mean (SEM). Comparisons were made using 
the Mann-Whitney U test to assess non-parametric 
independent data. The one-way analysis of variance 
(ANOVA) was used to evaluate parametric data. Differ-
ences were considered significant when P < 0.05.
Results
Stability of Liposomal Formulations 
Entrapping Loperamide HCl 
In order to circumvent potential solubility issues of 
loperamide HCl across the dialysis membrane, an assay 
was developed to assess the true release of loperamide 
HCl from the liposomes without surpassing the satura-
tion point. At a dilution of 200 µg of loperamide HCl in 
40 mL of PBS release volume, which equated to 200 µg 
of loperamide HCl in 10 mL of PBS within the dialysis 
tubing, minimal release was observed in both PBS and 
50% FCS at 37oC (Fig. 2A). The stability of the liposome 
formulation was slightly lower in 50% serum in com-
parison to PBS due to the bioactive substance in FCS, 
however the difference was not significant. The diffu-
sion of free drug through the dialysis membrane was 
also investigated with 100% of loperamide HCl solution 
being recovered in the dialysis medium within 6 hours 
as determined by HPLC, demonstrating that the release 
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Fig. 2. Stability of  liposomal formulations entrapping 
loperamide HCl. (A) Release of  loperamide HCl from 
nanoparticles in PBS pH 7.4 and 50% FCS at 37oC. 
The data represents the mean ± SEM as error bars of  3 
independent experiments (P > 0.05; Mann-Whitney U 
test). (B and C) Particle size and polydispersity index over 
a period of  7 days of  liposome formulation encapsulating 
loperamide HCl. The results are represented as mean ± SD 
of  3 independent experiments (P > 0.05, ANOVA).
A
B
C
of loperamide HCl was not limited by the dialysis mem-
brane. This confirms that loperamide HCl is able to run 
through the cellulose membrane tubing freely. In order 
to ensure stability of liposomes over time, experiments 
were conducted to monitor size and size distribution of 
the liposome formulation under storage conditions of 
4oC in PBS pH 7.4 over 7 days. The size and polydisper-
sity index of the liposome formulation are stable over 
this period (Fig. 2B and 2C). All liposomal formulations 
used in subsequent studies were stored at 4oC and used 
within 7 days of preparation.
Specificity of Immunoliposome Binding
To ensure the targeting efficacy of the liposome 
formulation was not affected following the incorpora-
tion of therapeutic molecules, the targeted liposomal 
system was assessed for specificity of binding and cel-
lular uptake in vitro on primary high endothelial venule 
(HEV) cells cultured from rat lymph nodes. The differ-
ent stages of growth of primary cultured HEV cells are 
depicted in Fig. 3A. At no stage was there more than 
one morphologically distinct type of cell present. To 
specifically identify HEV cells, immuno-labeling tech-
niques were incorporated utilizing the endothelial cell 
marker OX-43. OX-43 labeling was particularly intense 
for the heavily vesiculated HEV cells in comparison to 
the proliferated bipolar morphological form (Fig. 3B).
Binding of ICAM-1-targeted immunoliposomes 
incorporating loperamide HCl was determined from 
using fluorometric detection. As shown in Fig. 4A, 
ICAM-1-targeted immunoliposomes incorporating 
loperamide HCL  were capable of binding specifically 
to tumor necrosis factor-alpha (TNFα) activated endo-
thelial cells in vitro, with 93.21% increase in binding in 
comparison to non-inflammatory conditions (P < 0.01; 
Mann-Whitney U test). The binding of liposomes and 
rabbit IgG immunoliposomes are significantly lower 
than that of loperamide HCl-encapsulated anti-ICAM-1 
immunoliposomes to activated HEV cells (P < 0.01). 
The data also demonstrates the specificity of binding 
of loperamide HCl-encapsulated anti-ICAM-1 immu-
noliposomes to ICAM-1 expressing cells, as binding is 
significantly inhibited with preincubation with excess 
anti-ICAM-1 monoclonal antibodies (P < 0.01).
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Fig. 3. Phase contrast micrographs of  HEV cells in culture. 
(A) A. Primary HEV 
culture after 2 days showing 
a flat, vesiculated cell. B and 
C: Primary HEV culture 
after 3 - 4 days showing cells 
adopting varying morphologies 
and proliferating. D: Primary 
HEV culture after 6 days 
showing cell growth in many 
orientations. E and F: Primary 
HEV culture after 10 days 
showing confluent bipolar cells 
aligned in a parallel array. 
Scale bar, 50 µm. 
(B) Immunofluorescent 
staining of  primary 
cultured HEV cells with 
FITC-conjugated mouse 
anti-rat OX-43 monoclonal 
antibody. A and C: 
Photomicrographs of  
primary HEV cell culture. 
B and D: Corresponding 
fluorescent micrographs 
showing OX-43 labeling of  
rat endothelial cells (green). 
The data is representative 
of  10 fields on 3 
independent experiments. 
Scale bar, 50 µm.
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Degree of Cellular Uptake of 
Immunoliposomes
Cellular association of anti-ICAM-1 immunolipo-
somes with TNF-α-activated HEV cells was determined 
following an incubation time of 2 hours at 4oC and 5 
hours at 37oC before analysis by fluorescence micro-
plate spectroscopy. The degree of cellular uptake into 
vascular endothelial cells influences the proportion of 
nanoparticles able to undergo extravasation to the in-
jured tissue and release of encapsulated opioids to the 
Fig. 4. Fluorescence microplate spectroscopy data showing the cellular association of  nanoparticles to HEV cells. (A) Specificity 
of  binding to ICAM-1 on TNF-α activated and nonactivated HEV cells. Competitive inhibition of  binding of  loperamide HCl-
encapsulated anti-ICAM-1 immunoliposomes following preincubation of  TNF-α activated HEV cells with excess anti-ICAM-1 
monoclonal antibodies is also shown. Liposomes were incubated at 3.38 mM for a time period of  2 hours at 4oC. (B and C) 
Internalization of  nanoparticles by TNF-α activated HEV cells. Liposomes were incubated at (B) 5.79 mM or (C) 3.38 mM for 5 
hours at 37oC. The results are represented as mean ± SEM of  9 independent experiments (P < 0.01; Mann Whitney U test).
A
B
C
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site of action. After 5 hours incubation at 37oC, minimal 
cellular internalization was detected for loperamide 
HCl-encapsulated anti-ICAM-1 immunoliposomes, rab-
bit IgG immunoliposomes, and liposomes at both 5.79 
mM and 3.38 mM. Results following acid wash showed 
89.49% ± 1.48% of cell-bound anti-ICAM-1 immunoli-
posomes compared to 16.07% ± 5.71% for rabbit IgG 
immunoliposomes, and 8.72% ± 2.87% for liposomes 
at 5.79 mM (Fig. 4B). Cellular association following lipo-
some incubation at 3.38 mM resulted in similar findings 
(Fig. 4C). The data demonstrates that the cellular as-
sociation of loperamide HCl-encapsulated anti-ICAM-1 
immunoliposomes was due to binding to the surface of 
HEV cells, rather than cellular uptake (P < 0.01; Mann-
Whitney U test). In addition, no significant uptake of 
liposomes occurred at 4oC across all groups.
Effects of the Intraplantar Injection of 
Complete Freund’s Adjuvant (CFA)
Complete Freund’s Adjuvant (CFA) induced a lo-
cal inflammatory response characterized by unilateral 
oedema, hyperthermia, and hyperalgesia restricted to 
the inoculated hindpaw. Paw pressure thresholds 
(PPT) and paw volumes were measured before and 
after intraplantar CFA injection. The mean PPT value ± 
SEM (n = 36) before CFA injection was 162.3 ± 0.6 g 
for the inoculated hindpaw, and 161.6 ± 0.5 g for the 
contralateral hindpaw. The mean paw volume ± SEM as 
measured by displacement of the inoculated hindpaw 
was 1.026 ± 0.002 mL, and 1.043 ± 0.002 mL for the con-
tralateral hindpaw. The mean PPT value ± SEM at day 5 
following CFA injection of the inoculated hindpaw was 
61.6 ± 0.3 g, and the mean paw volume as measured 
by displacement was 2.051 ± 0.004 mL. Analysis of the 
contralateral hindpaw was not significantly different 
pre- and post-CFA injection (P > 0.05), with a mean 
PPT ± SEM of 164.0 ± 0.5 g and mean paw volume ± 
SEM as measured by displacement of 1.036 ± 0.002 mL. 
The results demonstrate an approximate doubling in 
volume size of the inoculated hindpaw in comparison 
to the contralateral paw (P < 0.0001). Analysis of PPT 
of the ipsilateral inflamed paws post-CFA injection 
demonstrated a significant reduction in comparison to 
contralateral paws (P < 0.0001) and measured baseline 
values prior to CFA injection (P < 0.0001).
Time Course of the Antinociceptive Effect
The peak and duration of the antinociceptive ef-
fect of loperamide HCl-encapsulated anti-ICAM-1 im-
munoliposomes was evaluated over 48 hours. Figure 
5A and 5B indicates that loperamide HCl-encapsulated 
anti-ICAM-1 immunoliposomes produced significant 
antinociception assessed by PPT on the ipsilateral 
(inflamed) paw of CFA-treated rats in comparison to 
the control groups (P < 0.01). In particular, the PPT of 
the loperamide HCL-encapsulated anti-ICAM-1 immu-
noliposome group was significantly higher at all time 
points from 1 hour to 48 hours in comparison to control 
groups. The results demonstrate a peak response at 
between 7 hours and 10 hours, which corresponds to 
a mean PPT value ± SEM (n = 6) of 127.5 ± 13.9 g and 
124.2 ± 15.1 g, respectively (P < 0.01). Furthermore the 
results indicate a significant antinociceptive effect ex-
tending over the 48 hours time frame of the study, with 
a mean PPT value ± SEM of 98.6 ± 13.0 g at 24 hours (P 
< 0.05) and 90.3 ± 8.4 g at 48 hours (P < 0.01). Efficacy of 
the same loperamide HCl-encapsulated delivery system 
with and without the ICAM-1 targeted ligand attached 
to the surface of the liposomes clearly indicates the sig-
nificant antinociceptive efficacy of the loperamide HCl-
encapsulated delivery carrier with the ICAM-1 targeted 
ligand. Empty anti-ICAM-1 immunoliposomes did not 
demonstrate any antinociceptive activity, which indi-
cates that the analgesic response was due to the release 
of loperamide HCl in the injured tissue. To examine opi-
oid receptor dependency of the antinociceptive actions, 
the peripheral opioid receptor antagonist, naloxone 
methiodide, was administered via intraplantar injec-
tion 15 minutes prior to loperamide-encapsulated anti-
ICAM-1 immunoliposomes. Naloxone methiodide was 
able to significantly reverse the antinociceptive effect 
of the loperamide-encapsulated targeted nanoparticles 
over the first 4 hours (P < 0.01), which corresponds to its 
duration of action. As the naloxone methiodide wears 
off, we can see a significant antinociceptive response at 
the 7 hours (P < 0.01) to 48 hours (P < 0.001) time points, 
which is likely to indicate a combination of exogenous 
loperamide-HCl and endogenous opioid activity. The 
mean PPT throughout the 48-hour period was not sig-
nificantly different between the other control groups, 
which indicates that loperamide HCl alone and the 
drug vehicle itself does not have any antinociceptive 
effect when administered systemically (P > 0.05). Paw 
pressure thresholds of the contralateral (non-inflamed) 
paw of control and loperamide HCl treatment groups 
were not significantly different compared to each other 
across all time points over the 48-hour period (Fig. 5A).
Time Course of the Anti-inflammatory Effect
Paw volume was used to assess inflammation in 
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Fig. 5. Time course of  the antinociceptive effects of  loperamide HCl-encapsulated anti-ICAM-1 immunoliposomes and control 
formulations in Complete Freund’s Adjuvant (CFA) treated animals. (A) Data is presented in terms of  paw pressure thresholds 
(PPT) of  the contralateral (non-inflamed) paw. (B) Data is presented in terms of  paw pressure threshold (PPT) of  the 
ipsilateral (inflamed) paw. Each point represents the mean PPT value ± SEM of  6 animals. Mann-Whitney U test was used to 
assess intergroup differences (*P < 0.05, **P < 0.01, ***P < 0.001).
A
B
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terms of displacement at baseline, 24 hours, and 48 
hours. No significant difference was seen for paw vol-
ume of the contralateral paws of all the study groups 
pre- and post-CFA injection (P > 0.05). The ipsilateral 
paws of the study groups at day 5 post-CFA injection 
have an approximate doubling in volume size com-
pared to the contralateral paws at baseline (P < 0.0001, 
Mann- Whitney U test, n = 36), which demonstrates a 
localized inflammatory response. At 24 hours and 48 
hours, the loperamide HCl-encapsulated anti-ICAM-1 
immunoliposome group demonstrated a significant de-
crease in paw volume with a mean displacement ± SEM 
(n = 6) of 1.753 ± 0.074 mL and 1.674 ± 0.081 mL, respec-
tively, in comparison to mean baseline displacement of 
2.110 ± 0.070 mL (P < 0.01, ANOVA, n = 6) (Fig. 6). The 
naloxone methiodide + loperamide-encapsulated anti-
ICAM-1 immunoliposome group also demonstrated an 
anti-inflammatory effect at 24 hours and 48 hours (P < 
0.01, ANOVA, n = 6). All other control groups showed 
Fig. 6. Time course of  the anti-inflammatory effects of  loperamide HCl-encapsulated anti- ICAM-1 immunoliposomes and 
control formulations in Complete Freund’s Adjuvant (CFA) treated animals. Data is presented in terms of  paw volume of  the 
ipsilateral (inflamed) paw. Each point represents the mean displacement volume ± SEM of  6 animals. ANOVA was used to 
assess differences relative to baseline (**P < 0.01).
no significant difference at 24 hours and 48 hours in 
comparison to baseline values (P > 0.05, ANOVA).
Effect of ICAM-1 Targeting on Tissue 
Distribution of Liposomes
Tissue biodistribution of the loperamide HCl-en-
capsulated anti-ICAM-1 immunoliposomes was assessed 
following intravenous administration in CFA-induced 
paw inflammation in rats. Loperamide HCl-encapsu-
lated liposomes acted as the control group. Studies 
were performed 5 days post-CFA injection, which corre-
sponded to peak inflammatory response. Rats were sac-
rificed 7 hours after liposome injection, and paw tissues 
and other indicated organs (brain, liver, and kidneys) 
were removed for processing of radioactivity using liq-
uid scintillation counting (LSC). Tissue distribution was 
evaluated at 7 hours post-liposome injection as peak 
antinociceptive efficacy of loperamide HCl-encapsulat-
ed anti-ICAM-1 immunoliposomes was demonstrated at 
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this time point in in vivo efficacy studies. The dose of 
radiolabelled liposomes injected intravenously per rat 
was equivalent to 7.41 x 104 Bq of [3H]-CHE.
Figure 7 shows the biodistribution of radiolabelled 
loperamide HCl-encapsulated anti-ICAM-1 immunolipo-
somes and radiolabelled loperamide HCl-encapsulated 
liposomes in CFA-induced paw inflammation in rats. 
Conjugation of anti-ICAM-1 monoclonal antibodies 
to the surface of long-circulating immunoliposomes 
increased the uptake into the inflamed paw tissue by 
3-fold at 7 hours in comparison to liposomes without 
the targeting ligand (P < 0.05, Mann-Whitney U test). 
The uptake of loperamide HCl-encapsulated ICAM-1 
targeted immunoliposomes into the inflamed paw 
tissue was 10.8-fold higher than uptake into the non-
inflamed paw tissue (P < 0.05). Minimal uptake into 
the brain was detected with no significant difference 
for both the ICAM-1 targeted immunoliposome and 
control formulation (P > 0.05), further demonstrating 
a peripheral opioid receptor-mediated effect. Corre-
spondingly, a 2-fold and 3-fold decrease in uptake of 
anti-ICAM-1 targeted immunoliposomes was detected 
in both the kidneys and liver, respectively, in compari-
son with the control (P < 0.05), which indicates that 
the targeted nanoparticles are not readily taken up 
by the reticuloendothelial system (RES) and hence are 
available for prolonged circulation and controlled re-
lease. Conversely, the control liposomes showed a large 
Fig. 7. Biodistribution of  [3H]-CHE radiolabelled loperamide HCl-encapsulated anti-ICAM-1 immunoliposomes and 
loperamide HCl-encapsulated liposomes in Complete Freund’s Adjuvant (CFA)-induced paw inflammation in rats. Rats were 
sacrificed 7 hours after intravenous injection of  200 µL of  liposome suspension (equivalent to 7.41 x 104 Bq). Each point 
represents the mean Bq per gram of  tissue ± SEM of  4 animals. Mann-Whitney U test was used to assess intergroup differences 
(*P < 0.05).
variability in uptake into the liver in comparison to the 
ICAM-1 targeted immunoliposomes. Comparison of the 
biodistribution into non-inflamed paw tissue showed a 
significant uptake of control liposomes in comparison 
with the loperamide HCl-encapsulated anti-ICAM-1 
immunoliposomes (P < 0.05). No significant difference 
in distribution to inflamed and non- inflamed paw tis-
sue was detected for the loperamide HCl-encapsulated 
liposome group (P > 0.05).
discussion
We have engineered targeted nanoparticles that 
are able to mimic the actions of endogenous opioid-
containing immune cells in response to tissue injury, to 
provide significant and prolonged analgesic and anti-
inflammatory effects. Incorporation of ICAM-1 target-
ing ligands to the surface of the liposomes increases 
localization to peripheral inflammatory tissue, thereby 
increasing the therapeutic potency of the targeted 
nanoparticles. ICAM-1 is a cell adhesion molecule that is 
upregulated and functionally involved in inflammation 
(7,23). It is localized to both the apical and basolateral 
surface of endothelial cells and does not undergo sig-
nificant internalization, making it ideally positioned to 
facilitate immune cell recruitment and transendothelial 
migration (24). Furthermore, ICAM-1 plays an impor-
tant role in peripheral analgesia at both the endothe-
lial (25,26) and immune cell-neuronal level (6). We have 
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demonstrated specific binding and minimal cellular 
uptake of the targeted nanoparticles to vascular endo-
thelial cells preincubated with the inflammatory cyto-
kine TNF-α, which allows extravasation of the targeted 
nanoparticles across the endothelial barrier directed by 
ICAM-1 on the surface of endothelial cells at sites of 
inflammation and the subsequent release of encapsu-
lated opioids in close vicinity to upregulated peripheral 
opioid receptors in injured tissue (1). This peripheral 
analgesic pathway has yet to be targeted in pharma-
ceutical formulation and clinical pain management.
Incorporation of loperamide HCl into ICAM-1 
targeted immunoliposomes allows the intravenous 
use of this antidiarrhoeal agent as a peripherally selec-
tive analgesic, which has not been achieved prior to 
this study. The antinociceptive effects of loperamide 
HCl have previously been observed in various models 
of chemical-induced inflammatory pain and constant 
thermal hyperalgesia after local (11,14,27) and systemic 
(subcutaneous) (13,14) routes of administration. Bind-
ing studies have demonstrated that loperamide HCl 
has a strong affinity and high selectivity for mu-opioid 
receptors (9,11,28), however it does not have analgesic 
effects when administered orally or intravenously due 
to its physicochemical properties (1,10-14). Its exclusion 
from the CNS is apparently due to its active removal by 
the multi-drug resistance transporter, its high affinity 
to lipid membranes, and its ability to decrease surface 
tension (11,14,27,28). This contributes to its accumula-
tion in membranes and subsequent lack of systemic ab-
sorption (27,28). After intravenous or oral application 
loperamide HCl becomes trapped in the liver, kidneys, 
and lungs, or stomach and intestines, respectively (27). 
Opioid-like antinociception in rodents after intravenous 
injection of the free drug occurs only at almost lethal 
doses (9). Encapsulation of loperamide HCl within long 
circulating ICAM-1-targeted immunoliposomes allows 
both prolonged circulation and active targeting to sites 
of inflammation, thereby allowing a lower dose to be 
administered systemically.
Under physiological conditions, solute leakage de-
pends not only on the intrinsic membrane permeability 
but also its interaction with components of the biologi-
cal fluid, which strongly affect liposome clearance (29). 
In vitro stability studies of the DSPC with cholesterol 
liposome formulation entrapping loperamide HCl have 
demonstrated highly stable vesicles upon dilution in an 
aqueous phase (PBS pH 7.4) and in serum (50% FCS). 
The results suggest that the targeted nanoparticles will 
be suitable for use in administration of loperamide HCl 
to sites of high dilution such as following intravenous 
administration. The minimal release of loperamide 
HCl from DSPC with cholesterol liposome formulations 
at 37oC may be attributed to the more stable outer 
surface of the liposome formulation, thereby keeping 
loperamide HCl entrapped in the lipid bilayer. Stability 
against leakage has been achieved using phospholipids 
(e.g., DSPC) that remain in the solid phase at physiologi-
cal temperatures. Incorporating cholesterol generally 
enhances bilayer stability against leakage by minimising 
lipid exchange (30). The ICAM-1 targeted immunolipo-
somes in this study have both a mean particle size of 
286 ± 7.9 nm and a neutral net charge, conferring long-
circulation half-lives. If the recognition of liposomes as 
a foreign body by the immune system can be circum-
vented, these vesicles could circulate in the bloodstream 
longer to interact with their target and even extravasate 
through leaky or fenestrated endothelium.
Peripheral inflammation enhances the effects of 
exogenously administered opioid agonists (1). We are 
the first to demonstrate that targeting the peripheral 
opioid system by mimicking opioid-containing immune 
cells has significant analgesic and anti-inflammatory 
effects. Loperamide HCl-encapsulated anti-ICAM-1 
immunoliposomes produced significant antinocicep-
tion over the 48 hour time course studied following 
intravenous administration, by specific localization of 
the targeted carrier to peripheral inflammatory tissue. 
This allows the release of loperamide HCl in close vicin-
ity to the upregulated peripheral opioid receptors in 
inflammation to provide site-directed antinociception 
(6). Evaluation of paw pressure thresholds (PPT) of the 
loperamide HCl-encapsulated anti-ICAM-1 immunoli-
posome group demonstrated a peak antinociceptive 
effect between 7 hours to 10 hours, and a significant 
prolonged antinociceptive response as assessed over 48 
hours. The controlled release effect may be due to the 
use of saturated phospholipids with high lipid phase 
transition temperatures (Tm), thus conferring both 
prolonged circulation (30,31) and specific release at 
sites of hyperthermia (32,33), which is a characteristic 
of inflammation.
It is unlikely that anti-ICAM-1 monoclonal antibod-
ies on the surface of the targeted liposomes blocked 
the function of ICAM-1 on the apical surface of vascular 
endothelial cells, and hindered the extravasation of im-
mune cells containing pro-inflammatory factors to cause 
the analgesic and anti-inflammatory effects. This is sup-
ported by the lack of analgesic and anti-inflammatory 
activity by empty anti-ICAM-1 immunoliposomes and 
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loperamide HCl-encapsulated liposomes, in comparison 
to the loperamide-encapsulated targeted nanoparticles. 
Administration of anti-ICAM-1 monoclonal antibodies at 
this concentration (25 µg) has not been previously dem-
onstrated to have analgesic or anti-inflammatory effects 
(34-36). More specifically when monoclonal antibodies 
targeting cell adhesion molecules are conjugated to 
liposomes, the carrier system either undergoes binding 
and extravasation, or cellular internalisation in inflam-
mation (37). The potential to inhibit leukocyte adhesion 
to the endothelium and thus extravasation into the in-
flammatory tissue only exists when administering high 
concentrations of free anti-ICAM-1 monoclonal antibod-
ies (34-36). For example, Ioculano et al (34) assayed the 
pathophysiological role of ICAM-1 in a model of isch-
aemia reperfusion in the rat. Intravenous administration 
of anti-rat ICAM-1 monoclonal antibodies at a dose of 1 
mg/kg, which equated to 250 – 360 µg, prior to occlusion 
of the left main coronary artery, significantly decreased 
leukocyte accumulation. Our data suggest that the tar-
geted nanoparticles may escape from the gaps between 
adjacent endothelial cells and openings at the vessel 
termini during inflammation by passive convective trans-
port and/or ligand-directed targeting (37,38).
This phenomenon of disease-site targeting is be-
lieved to play a major role in the enhanced efficacy 
observed for a variety of drugs when formulated inside 
lipid vesicles (39- 41). More importantly, Tosi et al (42) 
investigated the in vivo antinociceptive efficacy of pep-
tide-derivatised nanoparticles loaded with loperamide 
HCl for delivery to the CNS, and reported a peak per-
centage of maximum possible effect (% MPE) of 60% 
at 4 hours and a significant sustained release effect for 
6 hours after tail vein injection of a dose equivalent of 
0.7 mg of loperamide HCl in Wistar rats. The investiga-
tors reported that this long-lasting effect had not been 
shown before, with previous studies in the literature 
showing maximum antinociceptive effect at the same 
dose of loperamide HCl of between 15 minutes and 
1 hour, before a rapid decrease in antinociceptive ef-
ficacy (10,43). This is in contrast to our results, which 
shows a peak antinociceptive effect between 7 hours 
to 10 hours, and a significant and prolonged antino-
ciceptive effect over 48 hours following the intrave-
nous administration of long circulating loperamide 
HCl-encapsulated anti-ICAM-1 immunoliposomes, with 
a dose equivalent of 0.8 mg of loperamide HCl. In ad-
dition the antinociceptive activity of the loperamide 
HCl-encapsulated targeted immunoliposomes was able 
to be reversed with naloxone methiodide, which sug-
gest an opioid-receptor dependent analgesic effect. 
Naloxone methiodide has a relatively short duration 
of action, which our data confirms, showing that when 
administered via intraplantar injection, its effects last 
for approximately 4 hours.
There is growing evidence that opioid peptides are 
also potent modulators of cellular immune response, 
which can enhance or inhibit immune functions (1,44-
46). The analysis of paw volume following administra-
tion of loperamide HCl-encapsulated anti-ICAM-1 
immunoliposomes showed a significant decrease at 24 
hours and 48 hours in comparison to baseline displace-
ment values, even when naloxone methiodide was 
administered beforehand. As the duration of action 
of naloxone methiodide is relatively short, we did not 
expect this to affect the anti-inflammatory response of 
the targeted nanoparticles as anti-inflammatory action 
is never immediate. This is in contrast to the control 
groups, which did not demonstrate a significant change 
in paw volume assessed over 48 hours. It is plausible that 
the anti-inflammatory effect observed following admin-
istration of loperamide HCl-encapsulated anti-ICAM-1 
immunoliposomes is a result of opioid mediated inhibi-
tion of leukocyte recruitment to inflamed tissue (47-51), 
or partly due to opioid mediated detachment of immune 
cells from sensory neurons (6) – in this way preventing 
the release of cytokines and other inflammatory factors 
into the injured tissue. However, empty anti-ICAM-1 
immunoliposomes did not demonstrate any anti-inflam-
matory activity, making the former mechanism less likely. 
We have previously shown that opioids can interfere 
with the direct cell adhesion between immune cells 
and neurons via an opioid receptor dependent mecha-
nism, which may result in dissociation and migration of 
leukocytes back to regional lymph nodes (6). This is in 
contrast to morphine which has been reported to have 
anti-oedema effects in rats with carrageenan-induced 
inflammation of the paw (52), potentially as a result of 
down-regulation of adhesion molecules on endothelial 
cells necessary for leukocyte transmigration, via stimula-
tion of nitric oxide production (48). Our results highlight 
a novel anti-inflammatory role for peripheral opioid 
targeting with loperamide HCl.
Biodistribution studies of loperamide HCl-encap-
sulated ICAM-1 targeted immunoliposomes showed 
predominant targeting of the nanoparticles into pe-
ripheral inflamed tissue, with minimal accumulation in 
non-inflamed paw tissue and the brain. This confirms 
that the antinociceptive effect observed following 
intravenous administration of loperamide HCl-encap-
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sulated ICAM-1 targeted immunoliposomes was due 
to peripheral opioid receptor targeting, rather than 
a central opioid-mediated effect. As further support, 
the antinociceptive effect of the opioid-encapsulated 
targeted nanoparticles was able to be blocked with nal-
oxone methiodide. Loperamide HCl does not elicit an 
effect on the CNS when administered as the free drug 
form as it is a substrate for the multi-drug resistance 
transporter (11,14). ICAM-1 is also not normally upregu-
lated in the blood-brain barrier (BBB) or CNS (53,54). In 
addition, the significant anti-inflammatory effect fol-
lowing intravenous administration of loperamide HCl-
encapsulated anti-ICAM-1 immunoliposomes suggests a 
more localized response at the peripheral inflammatory 
site rather than distribution into the CNS. The biodistri-
bution data also shows limited uptake of the targeted 
nanoparticles by the reticuloendothelial system (RES) 
(e.g., liver, kidneys), which allows prolonged systemic 
circulation and controlled release. This is of importance 
as liposomes with entrapped materials have previously 
been rapidly cleared due to opsonisation of plasma 
components and uptake by fixed macrophages of the 
reticuloendothelial system (RES), thereby limiting their 
prospects as an in vivo delivery system for transporting 
drugs to sites of disease beyond the RES.
conclusion
The interaction of the immune system and nervous 
system in peripheral pain control is of significant clinical 
relevance. We have engineered targeted nanoparticles 
to mimic this interaction that takes place within injured 
tissue to provide peripherally selective analgesic and 
anti-inflammatory effects, using loperamide HCl. Al-
though the nociceptive and anti-inflammatory testing 
methods have been well established in the literature, 
future studies may consider using additional meth-
ods (e.g., assessing thermal hyperalgesia, or using an 
electronic von Frey anesthesiometer to assess mechani-
cal allodynia). It will be of much interest to elucidate 
the mechanism of the anti-inflammatory effect of 
loperamide HCl-encapsulated anti-ICAM-1 immunoli-
posomes. We are currently assessing the analgesic and 
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